Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.

M Behnia, R Foster, L H Einhorn, J Donohue, C R Nichols

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Two cycles of bleomycin, etoposide, and cisplatin (BEP) were evaluated as adjuvant chemotherapy for patients with pathological stage II non-seminomatous germ cell tumours. Between 1985 and 1995, 86 patients with pathological stage II non-seminomatous testicular cancer were treated with two cycles of BEP. At retroperitoneal lymph node dissection (RPLND) 49 patients (57%) had pathological stage II(A) (microscopic nodal metastases) and 37 (43%) had stage II(B) (gross nodal metastases). After RPLND, the patients received bleomycin, 30 units weekly for 8 weeks, etoposide (100 mg/m(2)) and cisplatin (20 mg/m(2)) each for 5 days every 28 days for two cycles as adjuvant chemotherapy. 4 patients were lost to follow-up. 10 patients (12%) developed granulocytopenic fever during their chemotherapy. Of the 82 evaluable patients all remained with no evidence of disease except for a single patient with a cervical nodal relapse of teratoma. This was resected and he remains disease free. Median follow
Original languageUndefined
Pages (from-to)472 - 475
JournalEuropean Journal of Cancer
Volume36
Issue number4
StatePublished - 2000

Keywords

  • Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Germinoma/*drug therapy, Testicular Neoplasms/*drug therapy, Bleomycin/administration & dosage, Chemotherapy, Adjuvant, Cisplatin/administration & dosage, Drug Administration Schedule, Etoposide/administration & dosage, Follow-Up Studies, Germinoma/pathology, Germinoma/surgery, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Retrospective Studies, Testicular Neoplasms/pathology, Testicular Neoplasms/surgery

Cite this

Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. / Behnia, M; Foster, R; Einhorn, L H; Donohue, J; Nichols, C R.

In: European Journal of Cancer, Vol. 36, No. 4, 2000, p. 472 - 475.

Research output: Contribution to journalArticle

@article{ebb15b88c52e4e49ad94d72bae1a08d3,
title = "Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.",
abstract = "Two cycles of bleomycin, etoposide, and cisplatin (BEP) were evaluated as adjuvant chemotherapy for patients with pathological stage II non-seminomatous germ cell tumours. Between 1985 and 1995, 86 patients with pathological stage II non-seminomatous testicular cancer were treated with two cycles of BEP. At retroperitoneal lymph node dissection (RPLND) 49 patients (57{\%}) had pathological stage II(A) (microscopic nodal metastases) and 37 (43{\%}) had stage II(B) (gross nodal metastases). After RPLND, the patients received bleomycin, 30 units weekly for 8 weeks, etoposide (100 mg/m(2)) and cisplatin (20 mg/m(2)) each for 5 days every 28 days for two cycles as adjuvant chemotherapy. 4 patients were lost to follow-up. 10 patients (12{\%}) developed granulocytopenic fever during their chemotherapy. Of the 82 evaluable patients all remained with no evidence of disease except for a single patient with a cervical nodal relapse of teratoma. This was resected and he remains disease free. Median follow",
keywords = "Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Germinoma/*drug therapy, Testicular Neoplasms/*drug therapy, Bleomycin/administration & dosage, Chemotherapy, Adjuvant, Cisplatin/administration & dosage, Drug Administration Schedule, Etoposide/administration & dosage, Follow-Up Studies, Germinoma/pathology, Germinoma/surgery, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Retrospective Studies, Testicular Neoplasms/pathology, Testicular Neoplasms/surgery",
author = "M Behnia and R Foster and Einhorn, {L H} and J Donohue and Nichols, {C R}",
year = "2000",
language = "Undefined",
volume = "36",
pages = "472 -- 475",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.

AU - Behnia, M

AU - Foster, R

AU - Einhorn, L H

AU - Donohue, J

AU - Nichols, C R

PY - 2000

Y1 - 2000

N2 - Two cycles of bleomycin, etoposide, and cisplatin (BEP) were evaluated as adjuvant chemotherapy for patients with pathological stage II non-seminomatous germ cell tumours. Between 1985 and 1995, 86 patients with pathological stage II non-seminomatous testicular cancer were treated with two cycles of BEP. At retroperitoneal lymph node dissection (RPLND) 49 patients (57%) had pathological stage II(A) (microscopic nodal metastases) and 37 (43%) had stage II(B) (gross nodal metastases). After RPLND, the patients received bleomycin, 30 units weekly for 8 weeks, etoposide (100 mg/m(2)) and cisplatin (20 mg/m(2)) each for 5 days every 28 days for two cycles as adjuvant chemotherapy. 4 patients were lost to follow-up. 10 patients (12%) developed granulocytopenic fever during their chemotherapy. Of the 82 evaluable patients all remained with no evidence of disease except for a single patient with a cervical nodal relapse of teratoma. This was resected and he remains disease free. Median follow

AB - Two cycles of bleomycin, etoposide, and cisplatin (BEP) were evaluated as adjuvant chemotherapy for patients with pathological stage II non-seminomatous germ cell tumours. Between 1985 and 1995, 86 patients with pathological stage II non-seminomatous testicular cancer were treated with two cycles of BEP. At retroperitoneal lymph node dissection (RPLND) 49 patients (57%) had pathological stage II(A) (microscopic nodal metastases) and 37 (43%) had stage II(B) (gross nodal metastases). After RPLND, the patients received bleomycin, 30 units weekly for 8 weeks, etoposide (100 mg/m(2)) and cisplatin (20 mg/m(2)) each for 5 days every 28 days for two cycles as adjuvant chemotherapy. 4 patients were lost to follow-up. 10 patients (12%) developed granulocytopenic fever during their chemotherapy. Of the 82 evaluable patients all remained with no evidence of disease except for a single patient with a cervical nodal relapse of teratoma. This was resected and he remains disease free. Median follow

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Germinoma/drug therapy, Testicular Neoplasms/drug therapy, Bleomycin/administration & dosage, Chemotherapy, Adjuvant, Cisplatin/administration & dosage, Drug Administration Schedule, Etoposid

M3 - Article

C2 - 10717522

VL - 36

SP - 472

EP - 475

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4

ER -